Scotland first part of UK to approve ‘cutting edge’ treatment for stomach cancer

Scotland first part of UK to approve ‘cutting edge’ treatment for stomach cancer

The Scottish Medicines Consortium has approved zolbetuximab – to be used together with chemotherapy – to treat those with advanced stomach cancer. Scotland has become the first part of the UK to approve a new treatment hailed as “cutting edge care” for patients with advanced stomach cancer. The Scottish Medicines Consortium (SMC) has given the go-ahead for the drug zolbetuximab to be used, together with chemotherapy. SMC vice-chair Dr Robert Pee…

Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment

Decision introduces zolbetuximab for eligible patients in NHS Scotland